Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilised Spikes (Vaccine Candidate)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies is vaccine candidate:
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes as a Single-Dose COVID-19 Vaccine:
NIAID researchers designed an investigational virus-like particle (VLP) vaccine for COVID-19. VLP vaccines use virus proteins to form a non-infectious particle that mimics a virus particle but does not replicate. For this vaccine, scientists combined proteins from Newcastle disease virus (which primarily infects poultry) and stabilized SARS-CoV-2 spike proteins. The vaccine candidate induced robust immunity against SARS-CoV-2 in animal models.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the licences||To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world|
|Technology||One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein.|
|Products||Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material.|
|Field of use||While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program.|
|Term||Continuing until the date the last Patent has lapsed, expired, or been invalidated|
|Scope of the grant||Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines|
|Sublicence||MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence|